In this collaboration, Sheba's world-class experts will work with FAU to develop and deliver educational programs, conduct research and build additional response and leadership capabilities in Florida.
A scientist's ground-breaking work on the basic mechanisms and biochemical basis of chronic pain and drug addiction have opened new avenues of research and identified novel drug targets for these disorders.
A novel study has found that "skinny fat" - the combination of low muscle mass and strength in the context of high fat mass - may be an important predictor of cognitive performance in older adults.
FAU's Comprehensive Center for Brain Health is now enrolling patients for the pioneering Alzheimer's Prevention Initiative Generation Program that is made up of two clinical trials.
A study led by an affiliate faculty member in FAU's Charles E. Schmidt College of Medicine is the first to use a 3D virtual reality headset to test this tool as a distraction method in a pediatric setting.
A study led by a researcher at FAU is the first to use gold-standard measures to show that antipsychotic medication use in youths adversely affects body fat and insulin sensitivity.
One of the country's leading neuroscientists has developed eight myths and truths about Alzheimer's disease to shed light on this form of dementia that causes problems with memory, thinking and behavior.
If the "eyes are the window to the soul," then new studies suggest that they may also be a window into diagnosing and treating attention-deficit/hyperactivity disorder and other dopamine-linked disorders.
Red, blue, and now white, brought new meaning for FAU's Charles E. Schmidt College of Medicine as five members of its graduating class proudly represented three branches of the U.S. military during graduation.
Researchers from FAU's Charles E. Schmidt College of Medicine have developed a novel approach to treat ischemic stroke and have joined forces with CHS Pharma, Inc., a South Florida-based biotechnology company.